ARGOS THERAPEUTICS INC (OTCMKTS:ARGS) Shorts Decreased By 91.01% As Of May 16, 2018

May 16, 2018 - By Lena Young

Argos Therapeutics, Inc. (OTCMKTS:ARGS) Corporate Logo

During Q4 2017 the big money sentiment increased to 0.85. That’s change of 0.22, from 2017Q3’s 0.63. 8 investors sold all, 5 reduced holdings as Argos Therapeutics, Inc. ratio improved. 5 rose positions while 6 funds bought positions. Funds hold 2.48 million shares thus 6.25% less from 2017Q3’s 2.64 million shares.
24,877 were accumulated by Guggenheim Capital Ltd Llc. Wasatch Advisors Incorporated reported 0% of its capital in Argos Therapeutics, Inc. (OTCMKTS:ARGS). New York-based National Bank Of Ny Mellon has invested 0% in Argos Therapeutics, Inc. (OTCMKTS:ARGS). 94,800 are owned by California Public Employees Retirement Systems. Meeder Asset Management has 0% invested in Argos Therapeutics, Inc. (OTCMKTS:ARGS) for 22,439 shs. State Street Corporation reported 11,900 shs. Blackrock accumulated 7,526 shs or 0% of the stock. Pennsylvania-based Vanguard Grp has invested 0% in Argos Therapeutics, Inc. (OTCMKTS:ARGS). Credit Suisse Ag has 0% invested in Argos Therapeutics, Inc. (OTCMKTS:ARGS). Stifel Financial reported 0% of its capital in Argos Therapeutics, Inc. (OTCMKTS:ARGS). The New York-based Morgan Stanley has invested 0% in Argos Therapeutics, Inc. (OTCMKTS:ARGS). 36 were accumulated by Deutsche Bank & Trust Ag. Virtu Fin Ltd Liability reported 0% in Argos Therapeutics, Inc. (OTCMKTS:ARGS). Two Sigma Secs Ltd Liability owns 47,961 shs. Keybank National Association Oh reported 119,515 shs.

ARGOS THERAPEUTICS INC (OTCMKTS:ARGS) reported a decrease of 91.01% in short interest. In May was published ARGS’s total 65,500 short interest by FINRA. The down change of 91.01% from 728,400 shares was reported.

ARGS is touching $0.172 during the last trading session, after decreased 9.43%.Currently Argos Therapeutics, Inc. is downtrending after 87.69% change in last May 16, 2017. ARGS has also 67,166 shares volume. The stock underperformed the S&P 500 by 99.24%.

Argos Therapeutics, Inc., an immuno-oncology company, focuses on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases in North America.The company has $1.82 million market cap. The firm develops immunotherapies based on its proprietary technology platform, Arcelis.Currently it has negative earnings. The Company’s product candidates include rocapuldencel-T, which is in Phase III clinical trial for the treatment of metastatic renal cell carcinoma; and in Phase II clinical trial to treat early stage renal cell carcinoma and muscle invasive bladder cancer.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: